Join the Acute Myeloid Leukemia group to help and get support from people like you.
Acute Myeloid Leukemia News
Related terms: Acute Granulocytic Leukemia, Acute Myelogenous Leukemia, ANLL, Cancer, Acute Granulocytic Leukemia, Cancer, Acute Myelogenous Leukemia, Cancer, Acute Myeloid Leukemia, Leukemia, Acute Granulocytic, Leukemia, Acute Myelogenous, Leukemia, Acute Myeloid, AML
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 – There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the highest in the United...
FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ – Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...
Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
THURSDAY, Oct. 24, 2024 – Protracted low-dose exposure to ionizing radiation among radiation-monitored workers is associated with mortality due to some hematologic malignancies, according to a study...
Overall Survival Improving for Umbilical Cord Blood Transplant
MONDAY, Oct. 7, 2024 – For umbilical cord blood transplant (UCBT), overall survival has improved over time, according to a study published in the October issue of Transplantation and Cellular...
Pharmacogenomic Score Can Personalize Treatment of Leukemia in Children
WEDNESDAY, Aug. 7, 2024 – For pediatric patients with acute myeloid leukemia (AML), a pharmacogenomics-based 10 single nucleotide polymorphism cytarabine (Ara-C) score (ACS10) can be used to tailor...
German Patient is 7th Person Probably Cured of HIV
FRIDAY, July 19, 2024 – A German man has become the seventh person to apparently be cured of HIV, researchers report. The 60-year-old man, referred to as the “next Berlin Patient,” was treated with a...
German Patient is 7th Person Probably Cured of HIV
FRIDAY, July 19, 2024 – A German man has become the seventh person to apparently be cured of HIV, researchers report. The 60-year-old man, referred to as the “next Berlin Patient,” was treated with a...
Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
WEDNESDAY, July 17, 2024 – Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the...
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
MONDAY, June 24, 2024 – For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD)...
ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia
WEDNESDAY, June 5, 2024 – For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with investigator-selected...
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
THURSDAY, May 16, 2024 – For older adults with acute myeloid leukemia (AML), venetoclax (VEN) combined with a hypomethylating agent (HMA) is safe and effective and can prolong survival, according to...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
TUESDAY, May 14, 2024 – Seniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted therapy for the blood cancer, a new study finds. The oral drug venetoclax is...
CD7 Expression Tied to Poorer Outcomes With Newly Diagnosed Leukemia
FRIDAY, May 3, 2024 – CD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), according to a study published online April 11 in the British...
FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
TOKYO & BASKING RIDGE, N.J. July 20, 2023 --(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that Vanflyta (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in...
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Rezlidhia is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML...